RxDoctor Payments Data

Nancy Tran, MD

Internal Medicine · Boston, MANPI 1780879189

Payments from drug & device makers

$1,338in general payments, 2019–2025

Across 70 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$188
  • Pfizer$169
  • Boehringer Ingelheim$147
  • Amgen$133
  • Johnson & Johnson$108
  • Takeda Pharmaceuticals U.S.A., Inc.$78
  • plus $515 from 13 others

What the payments were for

  • Food & beverage$1,338100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,338 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$175,805
Medicare patients
361
Services billed
2,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$113,756
OzempicSemaglutide23$36,888
XareltoRivaroxaban27$31,286
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$21,772
JardianceEmpagliflozin12$19,150
MyrbetriqMirabegron19$15,890
Atorvastatin Calcium441$8,025
Rosuvastatin Calcium272$7,639
Metoprolol Succinate274$6,442
Incruse ElliptaUmeclidinium Bromide15$6,315
Breo ElliptaFluticasone/Vilanterol11$6,221
Pravastatin Sodium206$5,708
Dexlansoprazole DrDexlansoprazole21$5,512
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$5,077
Olmesartan Medoxomil108$4,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$169$115,92794 claims
Novo NordiskOzempic$58$36,88823 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$31$34,30847 claims
Johnson & JohnsonXarelto$108$31,28627 claims
Boehringer IngelheimJardiance$147$19,15012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →